Frisch M, Biggar R J, Engels E A, Goedert J J
Danish Epidemiology Science Center, Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.
JAMA. 2001 Apr 4;285(13):1736-45. doi: 10.1001/jama.285.13.1736.
Large-scale studies are needed to determine if cancers other than Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer occur in excess in persons with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
To examine the general cancer pattern among adults with HIV/AIDS and to distinguish immunosuppression-associated cancers from other cancers that may occur in excess among persons with HIV/AIDS.
DESIGN, SETTING, AND SUBJECTS: Analysis of linked population-based AIDS and cancer registry data from 11 geographically diverse areas in the United States, including 302 834 adults aged 15 to 69 years with HIV/AIDS. The period of study varied by registry between 1978 and 1996.
Relative risks (RRs) of cancers, calculated by dividing the number of observed cancer cases by the number expected based on contemporaneous population-based incidence rates. We defined cancers potentially influenced by immunosuppression by 3 criteria: (1) elevated overall RR in the period from 60 months before to 27 months after AIDS; (2) elevated RR in the 4- to 27-month post-AIDS period; and (3) increasing trend in RR from before to after AIDS onset.
Expected excesses were observed for the AIDS-defining cancers, but non-AIDS-defining cancers also occurred in statistically significant excess (n = 4422; overall RR, 2.7; 95% confidence interval [CI], 2.7-2.8). Of individual cancers, only Hodgkin disease (n = 612; RR, 11.5; 95% CI, 10.6-12.5), particularly of the mixed cellularity (n = 217; RR, 18.3; 95% CI, 15.9-20.9) and lymphocytic depletion (n = 36; RR, 35.3; 95% CI, 24.7-48.8) subtypes; lung cancer (n = 808; RR, 4.5; 95% CI, 4.2-4.8); penile cancer (n = 14; RR, 3.9; 95% CI, 2.1-6.5); soft tissue malignancies (n = 78; RR, 3.3; 95% CI, 2.6-4.1); lip cancer (n = 20; RR, 3.1; 95% CI, 1.9-4.8); and testicular seminoma (n = 115; RR, 2.0; 95% CI, 1.7-2.4) met all 3 criteria for potential association with immunosuppression.
Although occurring in overall excess, most non-AIDS-defining cancers do not appear to be influenced by the advancing immunosuppression associated with HIV disease progression. Some cancers that met our criteria for potential association with immunosuppression may have occurred in excess in persons with HIV/AIDS because of heavy smoking (lung cancer), frequent exposure to human papillomavirus (penile cancer), or inaccurately recorded cases of Kaposi sarcoma (soft tissue malignancies) in these persons. However, Hodgkin disease, notably of the mixed cellularity and lymphocytic depletion subtypes, and possibly lip cancer and testicular seminoma may be genuinely influenced by immunosuppression.
需要开展大规模研究以确定除卡波西肉瘤、非霍奇金淋巴瘤和宫颈癌之外的其他癌症在感染人类免疫缺陷病毒(HIV)或患有获得性免疫缺陷综合征(AIDS)的人群中是否过度发生。
研究HIV/AIDS成人患者的总体癌症模式,并区分免疫抑制相关癌症与HIV/AIDS患者中可能过度发生的其他癌症。
设计、地点和研究对象:对来自美国11个地理区域的基于人群的艾滋病和癌症登记数据进行关联分析,包括302834名年龄在15至69岁之间的HIV/AIDS成人患者。各登记处的研究时间段在1978年至1996年之间有所不同。
癌症的相对风险(RRs),通过将观察到的癌症病例数除以基于同期人群发病率预期的病例数来计算。我们通过3条标准定义可能受免疫抑制影响的癌症:(1)在艾滋病前60个月至艾滋病后27个月期间总体RR升高;(2)在艾滋病后4至27个月期间RR升高;(3)从艾滋病发病前到发病后RR呈上升趋势。
观察到定义艾滋病的癌症出现预期的过度发生,但非定义艾滋病的癌症也在统计学上显著过度发生(n = 4422;总体RR,2.7;95%置信区间[CI],2.7 - 2.8)。在个体癌症中,只有霍奇金病(n = 612;RR,11.5;95% CI,10.6 - 12.5),特别是混合细胞型(n = 217;RR,18.3;95% CI,15.9 - 20.9)和淋巴细胞消减型(n = 36;RR,35.3;95% CI,24.7 - 48.8)亚型;肺癌(n = 808;RR,4.5;95% CI,4.2 - 4.8);阴茎癌(n = 14;RR,3.9;95% CI,2.1 - 6.5);软组织恶性肿瘤(n = 78;RR,3.3;95% CI,2.6 - 4.1);唇癌(n = 20;RR,3.1;95% CI,1.9 - 4.8);以及睾丸精原细胞瘤(n = 115;RR,2.0;9% CI,1.7 - 2.4)符合与免疫抑制潜在关联的所有3条标准。
尽管总体上癌症过度发生,但大多数非定义艾滋病的癌症似乎并未受到与HIV疾病进展相关的免疫抑制加重的影响。一些符合我们与免疫抑制潜在关联标准的癌症,在HIV/AIDS患者中过度发生可能是由于大量吸烟(肺癌)、频繁接触人乳头瘤病毒(阴茎癌)或这些患者中卡波西肉瘤(软组织恶性肿瘤)病例记录不准确。然而,霍奇金病,特别是混合细胞型和淋巴细胞消减型亚型,以及可能的唇癌和睾丸精原细胞瘤可能确实受到免疫抑制的影响。